An oral nano preparation and a preparation method thereof
An oral nano-formulation of isoliquiritin was prepared by combining corn protein, casein, soybean phospholipids and cholesterol, which solved the problem of poor water solubility of isoliquiritin and achieved a highly effective anti-tumor treatment effect, especially the inhibition of triple-negative breast cancer.
Patent Information
- Application Number
- CN202111474808.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-12-03
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2041-12-03
AI Technical Summary
In the existing technology, the application of active monomeric components of traditional Chinese medicine such as isoliquiritigenin in clinical anti-tumor treatment is limited due to poor water solubility, low oral absorption rate and rapid metabolism, especially the unsatisfactory treatment effect in triple-negative breast cancer.
A combination of corn protein, casein, soybean phospholipids and cholesterol was used as a drug carrier to prepare oral nanoparticles of isoliquiritigenin via an antisolvent method, forming nanoparticles with high encapsulation efficiency and small particle size, thereby enhancing bioavailability. The nanoparticles were then freeze-dried into lyophilized powder for easy transportation and storage.
It improves the bioavailability of isoliquiritigenin, achieving slow release in vitro and sustained release in vivo, significantly inhibiting the proliferation and migration of triple-negative breast cancer cells, reducing toxicity to normal cells, and providing a safe and effective anti-tumor treatment option.
Smart Images

Figure CN116211829B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of nano-biotechnology, and in particular to a novel oral nano-preparation and a preparation method thereof and application thereof in anti-tumor. Background Art
[0002] The incidence and mortality of malignant tumors continue to increase. Conventional treatments for cancer diseases are mostly surgery, radiotherapy and chemotherapy, but postoperative recurrence and metastasis, insensitivity to radiotherapy, and resistance to chemotherapy often occur, resulting in unsatisfactory clinical efficacy and a high probability of serious side effects.
[0003] In recent years, the incidence of breast cancer has remained the highest among female cancers worldwide. Among them, triple-negative breast cancer (TNBC) has no targeted treatment, is highly invasive, difficult to predict, and has a poor prognosis.
[0004] Nanoformulations are drugs prepared into nano-sized particles by different methods, including micelles, polymer nanoparticles, nanosuspensions, etc. Due to their large surface area, the drug dissolution rate and degree are both high, and nanoformulations have become one of the main methods to solve the problem of drug administration of poorly soluble drugs. At the same time, the drugs are mostly encapsulated inside the nanoparticles, and after entering the body, they can be isolated from the external environment for a certain period of time, thereby protecting unstable drugs to a certain extent and delaying metabolism. Nanoparticles within a certain particle size range (such as within 300nm) can also passively target tumors due to the EPR (enhanced permeation and retention) effect. Therefore, nano drug delivery systems are an effective means to solve the clinical application of poorly soluble drugs, especially poorly soluble anti-tumor drugs.
[0005] There have been many years of research on the effective active ingredients of traditional Chinese medicine for the prevention and treatment of cancer. Among them, isoliquiritigen (ISL) is a food-derived natural flavonoid compound with anti-tumor activity. Compared with chemotherapy drugs, it has low toxicity and side effects and high safety. In recent years, studies have also shown that isoliquiritigen and its derivatives can be used to treat leukemia. The latest studies have shown that isoliquiritigen has the ability to inhibit the migration of triple-negative breast cancer cells. Earlier studies have also reported that isoliquiritigen has the potential to inhibit the occurrence and development of triple-negative breast cancer in vivo. In recent years, many studies have also reported the application of curcumin nanoformulations in tumor treatment. However, due to poor water solubility, low oral absorption rate, and rapid metabolism, the active monomer components of traditional Chinese medicine, such as isoliquiritigen, are limited in clinical application. Summary of the invention
[0006] Therefore, the purpose of the present invention is to provide a novel oral nanoformulation encapsulating the active monomer component of traditional Chinese medicine isoliquiritigenin and a preparation method thereof, so as to improve its water solubility, enhance its in vivo uptake, and improve its bioavailability.
[0007] The inventors of the present invention creatively use a combination of corn protein, casein, soybean lecithin and cholesterol as a drug carrier to prepare isoliquiritigenin oral nanoformulations with high encapsulation rate and drug loading, stable nanoparticles, which can greatly increase the bioavailability of isoliquiritigenin after oral administration, achieving the ideal anti-cancer goal and formulation requirements.
[0008] In one aspect, the present invention provides an oral nanoformulation, comprising isoliquiritigenin and excipients, wherein the excipients include zein, casein, soybean lecithin and cholesterol.
[0009] Zein is a biological protein naturally produced from corn. Compared with animal proteins (such as gelatin and albumin), zein has the advantages of being renewable, degradable and cheap. As a hydrophobic corn protein material, it has been generally recognized as a safe (GRAS) biomaterial by the US FDA. It has good biocompatibility and is widely used as a bioengineering material and drug carrier material.
[0010] Sodium caseinate has excellent water solubility and an isoelectric point of about 4.5. It is an excellent stabilizer for Zein nanoparticles. By providing electrostatic and steric hindrance, it effectively improves the stability of Zein nanoparticles and has a high drug loading capacity. In addition, Zein, as an alcohol-soluble protein, is also often used as a coating material to protect drugs from damage to the gastrointestinal environment.
[0011] The molecular structure of soybean lecithin has a hydrophobic lipid end and a hydrophilic phosphoric acid and organic amine end, and can form a double-layer structure in water. Cholesterol is an amphiphilic substance and can be used as a liposome membrane material, emulsifier, ointment base and other pharmaceutical excipients. It plays an important role in improving the stability of liposome preparations, especially in liposome preparations. Experiments have shown that adding 30% to 50% cholesterol when preparing liposomes can provide good protection for the oxidative stability and physical stability of liposomes. Cholesterol can regulate the fluidity of liposome membranes, resist phospholipid oxidation, and play an important role in maintaining the stability of liposomes themselves and drug encapsulation rate.
[0012] According to the oral nano preparation provided by the present invention, the mass ratio of isoliquiritigenin to excipients can be 1:2-30, preferably 1:5-20.
[0013] Preferably, relative to 1 gram of isoliquiritigenin, the amount of zein is 0.2 to 2 grams, the amount of casein is 0.2 to 2 grams, the amount of soybean lecithin is 2 to 20 grams, and the amount of cholesterol is 1 to 5 grams.
[0014] More preferably, relative to 1 gram of isoliquiritigenin, the amount of zein is 0.2 to 1 gram, the amount of casein is 0.2 to 1 gram, the amount of soybean lecithin is 5 to 15 grams, and the amount of cholesterol is 1 to 4 grams.
[0015] Most preferably, with respect to 1 gram of isoliquiritigenin, the amount of zein is 0.2-0.5 gram, the amount of casein is 0.2-0.5 gram, the amount of soybean lecithin is 8-12 gram, and the amount of cholesterol is 1-3 gram.
[0016] The inventors have found that the oral nanoformulation of the present invention within the above preferred ratio range has a lower polydispersity index and better stability.
[0017] According to the oral nanoformulation provided by the present invention, the average particle size of the oral nanoformulation can range from 10 to 1000 nm, preferably from 20 to 200 nm. In the present invention, the oral nanoformulation can include oral nanomicelles, oral nanoparticles and oral nanosuspensions, etc. The solvent in the oral nanosuspension can be one or more of phosphate buffer, physiological saline and pure water.
[0018] According to the oral nano preparation provided by the present invention, the encapsulation rate of the oral nano preparation can reach up to 95%.
[0019] According to the oral nanoformulation provided by the present invention, the oral nanoformulation is used to treat or inhibit triple-negative breast cancer.
[0020] On the other hand, the present invention also provides a method for preparing an oral nanosuspension, the preparation method comprising the following steps:
[0021] (1) dissolving isoliquiritigenin, soybean lecithin, cholesterol and zein in an ethanol aqueous solution to prepare a solution A;
[0022] (2) dissolving casein in pure water to prepare solution B;
[0023] (3) Solution A is added dropwise into solution B, and the mixture is stirred until the ethanol is completely evaporated. The mixture is filtered through a filter membrane to obtain an oral nanosuspension.
[0024] The present invention adopts the method of anti-solvent method-ethanol injection to prepare an oral nanosuspension containing isoliquiritigenin, an active monomer component of traditional Chinese medicine. The anti-solvent method utilizes the different solubility of the drug in two solvents to produce a local supersaturated state when mixed, triggering nucleation, nuclear growth, coalescence and aggregation, and finally flocculating to form nanoparticles. The anti-solvent method is simple in preparing nanoparticles and is one of the main methods for preparing zein-related nanoparticles and liposomes. By adding different stabilizers, the nanoparticle size and structure can be changed, and a high encapsulation rate and drug loading can be guaranteed.
[0025] According to the method for preparing an oral nanosuspension provided by the present invention, the ethanol aqueous solution in step (1) can be a 60-95 wt % ethanol aqueous solution, preferably a 80-95 wt % ethanol aqueous solution.
[0026] According to the method for preparing an oral nanosuspension provided by the present invention, in step (1), preferably, relative to 1 gram of isoliquiritigenin, the amount of zein is 0.2 to 2 grams, the amount of soybean lecithin is 2 to 20 grams, the amount of cholesterol is 1 to 5 grams, and the amount of the ethanol aqueous solution is 0.2 to 2 liters.
[0027] Further preferably, relative to 1 gram of isoliquiritigenin, the amount of zein is 0.2-1 gram, the amount of soybean lecithin is 5-15 grams, the amount of cholesterol is 1-4 grams, and the amount of ethanol aqueous solution is 0.2-1 liter.
[0028] Most preferably, relative to 1 gram of isoliquiritigenin, the amount of zein is 0.2-0.5 gram, the amount of soybean lecithin is 8-12 grams, the amount of cholesterol is 1-3 grams, and the amount of the ethanol aqueous solution is 0.2-0.5 liter.
[0029] According to the method for preparing an oral nanosuspension provided by the present invention, in step (2), preferably, the amount of casein used is 0.2 to 2 grams, and the amount of pure water used is 1 to 10 liters relative to 1 gram of isoliquiritigenin. Further preferably, the amount of casein used is 0.2 to 1 gram, and the amount of pure water used is 2 to 8 liters relative to 1 gram of isoliquiritigenin. Most preferably, the amount of casein used is 0.2 to 0.5 grams, and the amount of pure water used is 2 to 6 liters relative to 1 gram of isoliquiritigenin.
[0030] Preferably, the volume ratio of solution A (also referred to as "organic phase") obtained in step (1) to solution B (also referred to as "aqueous phase") obtained in step (2) is 1:2-5.
[0031] According to the method for preparing an oral nanosuspension provided by the present invention, preferably, in step (3), magnetic heating and stirring are adopted, the rotation speed can be 400-1000 r / min, the heating temperature can be 35-50° C., and the heating and stirring time can be 1-6 h.
[0032] According to the method for preparing an oral nanosuspension provided by the present invention, the filter membrane in step (3) can be, for example, a 0.45 μm filter membrane.
[0033] On the other hand, the present invention also provides a method for preparing oral nanoparticles, the preparation method comprising the following steps:
[0034] (1) dissolving isoliquiritigenin, soybean lecithin, cholesterol and zein in an ethanol aqueous solution to prepare a solution A;
[0035] (2) dissolving casein in pure water to prepare solution B;
[0036] (3) adding solution A dropwise into solution B, stirring until the ethanol is completely evaporated, and filtering with a filter membrane to obtain a nanosuspension;
[0037] (4) adding a protective agent to the nanosuspension prepared in step (3) and freeze-drying the nanosuspension to prepare a freeze-dried powder.
[0038] In this method, the nanosuspension is prepared into a freeze-dried powder to facilitate the transportation and storage of the nanopreparation, and it is more convenient to control the dosage when administering the drug. Vacuum freeze-drying technology is a drying technology that freezes wet materials or solutions into a solid state at a relatively low temperature (-10°C to -50°C), and then sublimates the water therein into a gaseous state without passing through a liquid state under a vacuum (1.3 to 13Pa), and finally dehydrates the material. Freeze-drying is completed under vacuum and low temperature conditions, so it is not easy to oxidize and denature, and the physical and chemical properties of the nanopreparation can be maintained to the maximum extent. After adding a freeze-drying protective agent, the solid ice crystals sublimate into a loose porous (sponge-like) structure formed after water vapor, which makes the nanopreparation have excellent solubility and rehydration, and can quickly absorb water and dissolve to restore its original properties. The freeze-dried nanopreparation is completely dehydrated, has a low water content, and is light in weight, which is suitable for long-distance transportation and long-term storage.
[0039] According to the method for preparing oral nanoparticles provided by the present invention, the protective agent can be one or more of trehalose, mannose, mannitol, and sucrose. The amount of the protective agent can be 2 to 10% (g / 100mL), preferably 4 to 6% (g / 100mL). Mannose is preferably used as a freeze-drying protective agent.
[0040] According to the method for preparing oral nanoparticles provided by the present invention, the ethanol aqueous solution in step (1) can be a 60-95 wt % ethanol aqueous solution, preferably a 80-95 wt % ethanol aqueous solution.
[0041] According to the method for preparing oral nanoparticles provided by the present invention, in step (1), preferably, relative to 1 gram of isoliquiritigenin, the amount of zein is 0.2 to 2 grams, the amount of soybean lecithin is 2 to 20 grams, the amount of cholesterol is 1 to 5 grams, and the amount of the ethanol aqueous solution is 0.2 to 2 liters.
[0042] Further preferably, relative to 1 gram of isoliquiritigenin, the amount of zein is 0.2-1 gram, the amount of soybean lecithin is 5-15 grams, the amount of cholesterol is 1-4 grams, and the amount of ethanol aqueous solution is 0.2-1 liter.
[0043] Most preferably, relative to 1 gram of isoliquiritigenin, the amount of zein is 0.2-0.5 gram, the amount of soybean lecithin is 8-12 grams, the amount of cholesterol is 1-3 grams, and the amount of the ethanol aqueous solution is 0.2-0.5 liter.
[0044] According to the method for preparing oral nanoparticles provided by the present invention, in step (2), preferably, the amount of casein used is 0.2 to 2 grams, and the amount of pure water used is 1 to 10 liters relative to 1 gram of isoliquiritigenin. Further preferably, the amount of casein used is 0.2 to 1 gram, and the amount of pure water used is 2 to 8 liters relative to 1 gram of isoliquiritigenin. Most preferably, the amount of casein used is 0.2 to 0.5 grams, and the amount of pure water used is 2 to 6 liters relative to 1 gram of isoliquiritigenin.
[0045] Preferably, the volume ratio of solution A (also referred to as "organic phase") obtained in step (1) to solution B (also referred to as "aqueous phase") obtained in step (2) is 1:2-5.
[0046] According to the method for preparing oral nanoparticles provided by the present invention, preferably, in step (3), magnetic heating and stirring are adopted, the rotation speed can be 400-1000 r / min, the heating temperature can be 35-50° C., and the heating and stirring time can be 1-6 h.
[0047] According to the method for preparing oral nanoparticles provided by the present invention, the filter membrane in step (3) can be, for example, a 0.45 μm filter membrane.
[0048] The advantages of the nano preparation of the present invention are: (1) the prescription is simple, containing only drugs and stabilizers, and the production process is simple and convenient; (2) the encapsulation rate can be as high as 95%, and the average particle size is less than 200nm, which has a very high drug transmission efficiency; (3) it is stable in artificial gastric juice, and there is no sudden release in vitro, and it can be slowly released, which is convenient for oral administration; (4) after freeze drying, the nano freeze-dried powder has excellent instant solubility and rehydration, and can quickly absorb water and dissolve to restore its original properties. The freeze-dried nano preparation is completely dehydrated, has a low water content, is light in weight, is suitable for long-distance transportation and long-term storage, and can better control the dosage of the drug; (5) the present invention provides innovative thinking for the modernization of the research on the preparation of active monomer components of traditional Chinese medicine, and lays a foundation for the application of licorice active component isoliquiritigenin in anti-tumor drugs. The present invention aims to research and develop safe, controllable and effective modern traditional Chinese medicine natural component nanoparticles.
[0049] The present invention prepared a novel oral isoliquiritigenin nanoformulation and evaluated its in vivo uptake and tumor suppressive activity against triple-negative breast cancer. The results showed that the oral isoliquiritigenin nanoformulation had a strong ability to inhibit the proliferation and migration of triple-negative breast cancer cells in vitro, and had low cytotoxicity to normal breast cells and normal liver cells; at the same time, the in vivo antitumor activity of the oral isoliquiritigenin nanoformulation in a tumor-bearing mouse model was significantly higher than that of the free isoliquiritigenin compound, and its clinical application prospect was good.
[0050] Although zein, casein, lecithin, and cholesterol are widely reported to be used for preparing nanoparticles, there are no reports on the nanocarrier structure and carrier excipient combination of the novel oral nanoformulation provided by the present invention, which is a novel oral nano drug delivery system different from the related reports. Zein, as one of the skeleton structures of oral nanocarriers, can protect the stability of nanocarriers in the gastrointestinal environment, casein, as a stabilizer, can stabilize the nanostructure during the self-assembly process of nanoparticles, and lecithin, because of its phospholipid bilayer, can be used to effectively load poorly soluble drugs and ensure the good biocompatibility of oral nanoparticles of active monomer components of traditional Chinese medicine. Cholesterol stabilizes the phospholipid bimolecular structure as a membrane stabilizer. In addition, the selection of nanocarrier excipients involved in the present invention all belongs to food-derived carrier materials, and inorganic materials are not used as carrier materials. Toxic reagents such as dimethyl sulfoxide, acetone, chloroform, methanol and other toxic organic reagents are not used in the preparation process. The preparation process of the oral nanoformulation of isoliquiritigenin of the present invention is simple, which is conducive to the industrial large-scale production of oral nanoformulation of isoliquiritigenin. The preparation method is simple, the drug loading capacity is high, and the stability is high. It can achieve the sustained release of isoliquiritigenin in vivo and in vitro, improve the bioavailability, improve its distribution in the body, and enhance the efficacy of anti-breast cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0051] The embodiments of the present invention are described in detail below with reference to the accompanying drawings, wherein:
[0052] Figure 1 Appearance photos of the oral nanoformulation of isoliquiritigenin prepared in Example 1 of the present invention and the blank control sample prepared in Comparative Example 1;
[0053] Figure 2 This is a transmission electron microscopy image of the oral nanoformulation of isoliquiritigenin prepared in Example 1 of the present invention;
[0054] Figure 3 This is a particle size distribution diagram of the oral nanoformulation of isoliquiritigenin prepared in Example 1 of the present invention;
[0055] Figure 4 This is the potential distribution diagram of the oral nanoformulation of isoliquiritigenin prepared in Example 1 of the present invention;
[0056] Figure 5 The in vitro release curves of the oral isoliquiritigenin nanoformulation (isoliquiritigenin nanoformulation) and free isoliquiritigenin in artificial gastrointestinal fluid prepared in Example 1 of the present invention (n=3);
[0057] Figure 6 The storage stability of the oral nanoformulation of isoliquiritigenin prepared in Example 1 of the present invention;
[0058] Figure 7 The mouse tissue distribution of the oral nanoformulation of the present invention encapsulating the DiR (MB12482) fluorescent probe was compared with isoliquiritigenin;
[0059] Figure 8 To investigate the gastrointestinal uptake capacity of the oral nanoformulation of the present invention encapsulating coumarin in mice;
[0060] Fig. 9 The figure is a comparison of the in vitro cancer cell proliferation inhibition abilities of isoliquiritigenin and the isoliquiritigenin oral nanoformulation of the present invention;
[0061] Fig.10 The cytotoxicity of free isoliquiritigenin and the oral nanoformulation of isoliquiritigenin of the present invention is compared;
[0062] Fig.11 The in vivo antitumor activity of the oral nanoformulation of isoliquiritigenin of the present invention. DETAILED DESCRIPTION
[0063] The present invention is further described in detail below in conjunction with specific embodiments. The given examples are only for illustrating the present invention, rather than for limiting the scope of the present invention.
[0064] The corn protein used in the following Example 1 and Comparative Example 1 was purchased from Tokyo Chemical Industry Co., Ltd., soybean lecithin was purchased from Avituo (Shanghai) Pharmaceutical Technology Co., Ltd., cholesterol was purchased from Aladdin, and casein and isoliquiritigenin were purchased from Shanghai Adamas Reagent Co., Ltd.
[0065] Example 1
[0066] Preparation of isoliquiritigenin oral nano preparation of the present invention
[0067] (1) Dissolve 3 mg of isoliquiritigenin, 1 mg of zein, 30 mg of soybean lecithin, and 6 mg of cholesterol in 2 mL of 90% ethanol;
[0068] (2) Dissolve 1 mg of casein in 10 mL of pure water;
[0069] (3) Under the conditions of 50° C. and 600 r / min magnetic stirring, 2 mL of the organic phase obtained in step (1) was slowly dripped into 10 mL of the aqueous phase obtained in step (2), and after stirring for 2 h, the ethanol was evaporated and filtered through a 0.45 μm filter membrane to obtain the oral nano preparation of isoliquiritigenin of the present invention.
[0070] Comparative Example 1
[0071] Preparation of blank oral nanoformulations
[0072] Dissolve 1 mg of corn protein, 30 mg of soybean lecithin, and 6 mg of cholesterol in 2 mL of 90% ethanol; dissolve 1 mg of casein in 10 mL of pure water; slowly drop 2 mL of the organic phase into 10 mL of the aqueous phase at 50°C and 600 r / min magnetic stirring conditions, stir for 2 hours, evaporate the ethanol, and filter through a 0.45 μm filter membrane to obtain a blank oral nanoformulation.
[0073] Characterization of formulations
[0074] Figure 1 The appearance photos of the oral nanoformulation of isoliquiritigenin prepared in Example 1 of the present invention (right) and the blank control sample (right) prepared in Comparative Example 1. The appearance of the blank oral nanoformulation and the oral nanoformulation of isoliquiritigenin is uniform and has opalescence.
[0075] Take an appropriate amount of nano-preparation, dilute it 10 times and drop it on the copper mesh. After absorbing the water with filter paper, dry it and place it in the selected area of the transmission electron microscope to take pictures and observe the morphology of the particles. Figure 2This is a transmission electron micrograph of the oral nanoformulation of isoliquiritigenin prepared in Example 1 of the present invention. The average particle size of the blank oral nanoformulation is 70.69 nm, the average Zeta potential is -16.83 mV, and the polydispersity index is 18.54%. The particle morphology of the oral nanoformulation of isoliquiritigenin observed under a transmission electron microscope is relatively round and uniform ( Figure 2 The average particle size of the oral nanoformulation of isoliquiritigenin is 73.24 nm ( Figure 3 ), the average Zeta potential is -17.21mV( Figure 4 ), the polydispersity index was 19.70%, the encapsulation efficiency was 96.75%, and the drug loading was 6.56%.
[0076] Example 2
[0077] In vitro release of isoliquiritigenin from oral nanoformulation in artificial gastrointestinal fluid
[0078] Pepsin and trypsin were purchased from Aladdin, potassium dihydrogen phosphate and sodium hydroxide were purchased from Cologne Chemicals Co., Ltd., and dialysis bags were purchased from Shanghai Baoman Biotechnology Co., Ltd.
[0079] Preparation of artificial gastric juice: Take 16.4 mL of 1.0 mol / L dilute hydrochloric acid, add 800 mL of distilled water and 10 g of pepsin, mix well, and dilute to 1000 mL with water.
[0080] Preparation of artificial intestinal fluid: weigh 6.8g potassium dihydrogen phosphate, add 500mL water, adjust the pH to 6.8 with 0.1mol / L sodium hydroxide, take 10g trypsin, dissolve it in water, mix the two liquids and dilute with water to 1000mL.
[0081] Test scheme: Take 2.0 mL (three parallel copies) of the oral nanoformulation of isoliquiritigenin prepared in Example 1 and 2 mL (three parallel copies) of free isoliquiritigenin dissolved in DMSO, place them in 35 mL of release medium in a ready-to-use dialysis bag (MWCO=3500), stir at 100 rpm at 37°C, regularly draw 1 mL of release medium, and then add an equal volume of new release medium. Add 1 mL of methanol to the taken release medium and ultrasonically break the emulsion for 20 min. Determine the content of ISL by HPLC, and calculate the cumulative release rate.
[0082] Test results: Figure 5The in vitro release curves of the oral nanoformulation of isoliquiritigenin (ISL@ZLH NPs) and free isoliquiritigenin (ISL-Free) prepared in Example 1 of the present invention in artificial gastrointestinal fluid (n=3). According to in vitro studies, the cumulative release of the free ISL group reached 71.77±3.72% in the first 2 hours. The free ISL group was completely released after 6 hours. Compared with the free ISL group, the oral nanoformulation has a significant sustained release effect in vitro, and can be slowly released for 24 hours, with a release rate of 89.5% of free isoliquiritigenin. The results show that the tight encapsulation of zein and the phospholipid bilayer can increase the liposome loading rate of ISL, thereby preventing excessive release of the drug in vitro.
[0083] Example 3
[0084] Evaluation of the gastrointestinal uptake capacity and tissue distribution of oral nanoformulations in mice
[0085] It is very important to study the in vivo absorption process of oral nanoformulations after administration. The in vivo imager (IVIS LuminaX5 Imaging System, Perkin-Elmer, Waltham, MA, US) can effectively observe the real-time distribution of drugs in animal tissues.
[0086] 1. Preparation of free DiR and DiR-loaded oral nanoformulations
[0087] Preparation of free DiR: Weigh 10 mg of DiR powder and dissolve it in 2 mL of anhydrous ethanol to prepare a 5 mg / mL DiR stock solution, which is diluted to an appropriate concentration with normal saline before administration.
[0088] Preparation of oral nanoformulations encapsulating DiR: Weigh 10 mg of DiR powder and dissolve it in 2 mL of anhydrous ethanol to prepare 5 mg / mL DiR mother solution; weigh 1 mg of corn protein, 30 mg of soybean lecithin, and 6 mg of cholesterol, dissolve them in 1 mL of 90% ethanol, and then add 1 mL of DiR mother solution to fully dissolve to form an organic phase; dissolve 1 mg of casein in 10 mL of pure water; slowly drip 2 mL of organic phase into 10 mL of aqueous phase at 50°C and 600 r / min magnetic stirring conditions, and stir for 2 h.
[0089] Test plan: After oral gavage of 10 mg / kg free DiR and oral nanoformulations encapsulated with DiR (DiR nanoformulations), the mice were gas anesthetized at 0.5, 1, 2 and 4 h, respectively, and placed in a near-infrared in vivo imaging system for observation. After 24 h, the mice were killed, and the heart, liver, spleen, lungs, kidneys, tumors, and gastrointestinal tract were removed for observation. The detection wavelengths were 745 and 790 nm, and the distribution and residence time of the oral nanoformulations in the gastrointestinal tract were analyzed by the intensity of the fluorescence signal.
[0090] 2. Preparation of free coumarin and coumarin-loaded oral nanoformulations
[0091] Preparation of free coumarin: Weigh 4 mg of coumarin 6 powder, dissolve it in 2 mL of anhydrous ethanol, and pass it through a 0.22 μm filter membrane.
[0092] Preparation of oral nanoformulations containing coumarin: Weigh 4 mg of coumarin 6 powder, dissolve it in 2 mL of anhydrous ethanol, and filter it through a 0.22 μm filter membrane; weigh 1 mg of corn protein, 30 mg of soybean lecithin, and 6 mg of cholesterol, dissolve them in 1 mL of 90% ethanol, and then add 1 mL of coumarin 6 filtrate to fully dissolve and form an organic phase; dissolve 1 mg of casein in 10 mL of pure water; slowly drip 2 mL of the organic phase into 10 mL of the aqueous phase at 50°C and 600 r / min magnetic stirring, stir for 2 hours, and filter it through a 0.45 μm filter membrane.
[0093] Test scheme: 10 μg / kg free coumarin and oral nanoformulations (coumarin nanoformulations) were administered by oral gavage for 6 hours, and then the mice were killed, the stomach and small intestine were separated, fixed in 4% paraformaldehyde fixative (PFA), frozen and sectioned, and observed and photographed under a confocal laser scanning microscope (CLSM) with a detection wavelength of 488 nm. The fluorescence intensity was analyzed using Image J software.
[0094] Test results: The oral nanoformulation containing DiR fluorescent probe is easier to enter the gastrointestinal tract of mice, and its intestinal penetration (2h) and retention time (24h) are better than those of free DiR. Figure 7 As shown, after 24 hours, each organ was taken out to analyze the tissue distribution of free DiR and oral nanoformulations containing DiR fluorescent probes. It was found that both were mainly enriched in the liver, and the signal of the oral nanoformulation group containing DiR fluorescent probes in the liver was significantly higher than that of the free DiR group, and the fluorescence signal was enhanced by about 1.25 times. Figure 8 As shown, the fluorescence intensity of the oral nanoformulation group (Coumarin-6@ZLH NPs) encapsulated with C6 in the small intestine is significantly higher than that of the free C6 group, and the fluorescence signal is enhanced by about 1.75 times, indicating that the oral nanoformulation encapsulated with C6 is more easily absorbed by the small intestine. In summary, the oral nanoformulation developed by the present invention has a good gastrointestinal uptake ability in mice, and it has a sustained release effect, which effectively prolongs the circulation time of the drug in the body.
[0095] Example 4
[0096] Evaluation of the ability of isoliquiritigenin and isoliquiritigenin oral nanoformulation to inhibit cancer cell proliferation in vitro
[0097] 1. Experimental methods
[0098] The isoliquiritigenin oral nanoformulation prepared in Example 1 and free isoliquiritigenin dissolved in DMSO were used for experiments.
[0099] RPMI-1640 and DMEM culture media, fetal bovine serum (FBS), and trypsin were purchased from Gibco (Lifetechnologies corporation). Dimethyl sulfoxide (DMSO) and MTT were products of Sigma (USA). Isoliquiritigenin was purchased from Alpha Aesar. The DMSO stock solution used in the in vitro experiments was diluted with 10% FBS complete culture medium to a final concentration of 0.1% (v / v).
[0100] Normal human breast cells MCF-10A, human triple-negative breast cancer cells MDA-MB-231 and BT-549 were purchased from ATCC, USA. Complete culture medium was prepared according to the instructions, and cells were cultured in a 5% CO2, 37°C incubator. When the cell density reached 70-80%, subculture was performed.
[0101] The MTT method was used to detect the inhibitory ability of isoliquiritigenin and isoliquiritigenin oral nanoparticles on the in vitro cell proliferation of triple-negative breast cancer cells MDA-MB-231 and BT-549. The cells were collected and inoculated into 96-well plates at a cell concentration of 3000-5000 cells per 100 μL. After 24 hours, the gradient concentrations of 5, 10, 20, 40, 80 and 160 μM of isoliquiritigenin and isoliquiritigenin oral nanoparticles were prepared in a culture medium containing 2% FBS and added to the cells. After 48 hours of culture in a cell culture incubator, 5 mg / mL of MTT sterile stock solution was added to the culture medium at a volume ratio of (5:1). After 2 to 4 hours, the upper layer of liquid was aspirated, DMSO was added to dissolve the lysed cells, and the absorbance value at 490 nm was read (OD value).
[0102] According to the formula: cell viability = (OD 490nm sample / drug-free control group) × 100%, the cell proliferation inhibition rate was calculated, and the half-maximal inhibition concentration of isoliquiritigenin and isoliquiritigenin oral nanoformulation on each cell was counted. The experiment was repeated three times, and the mean value (mean ± SD) was calculated.
[0103] 2. Experimental results
[0104] The proliferation inhibition activity of isoliquiritigenin and isoliquiritigenin oral nanoformulation on various cells Fig. 9 The results of the proliferation inhibition activity (IC50) on triple-negative breast cancer cells are shown in Table 1.
[0105] Table 1
[0106]
[0107] As can be seen from Table 1, the oral nanoformulation of isoliquiritigenin of the present invention has significantly better inhibitory activity against two triple-negative breast cancer cell lines, MDA-MB-231 and BT-549, than free isoliquiritigenin. The results show that the oral nanoformulation of isoliquiritigenin of the present invention has advantages in inhibiting tumor cell proliferation activity in vitro.
[0108] Example 5
[0109] Cytotoxicity evaluation of free isoliquiritigenin compounds and isoliquiritigenin oral nanoformulations 1. Experimental methods
[0110] The isoliquiritigenin oral nanoformulation prepared in Example 1 and free isoliquiritigenin dissolved in DMSO were used for experiments.
[0111] Human breast normal cells MCF-10A, human normal liver cells MIHA, mouse triple-negative breast cancer cells 4T1, etc. were purchased from ATCC, USA. Complete culture medium was prepared according to the instructions, and cells were cultured in a 5% CO2, 37°C incubator. When the cell density reached 70-80%, subculture was performed.
[0112] The MTT method was used to detect the cytotoxicity of isoliquiritigenin and isoliquiritigenin oral nanoparticles on MIHA, MCF-10A and 4T1 cells. The cells were collected and inoculated into 96-well plates at a cell concentration of 10,000 cells per 100 μL. After 24 hours, the gradient concentrations of 5, 10, 20, 40 and 80 μM of isoliquiritigenin and isoliquiritigenin oral nanoparticles were prepared in a culture medium containing 2% FBS and added to the cells. After culturing in a cell culture incubator for 24 hours, 5 mg / mL of MTT sterile stock solution was added to the culture medium at a volume ratio of (5:1). After 2-4 hours, the upper liquid was aspirated, DMSO was added to dissolve the lysed cells, and the absorbance value at 490 nm was read (OD value).
[0113] The cell survival rate was calculated as follows: cell survival rate = (OD 490nm sample / drug-free control group) × 100%. The survival rate of each cell treated with isoliquiritigenin and isoliquiritigenin oral nanoformulation was calculated and counted according to the formula, repeated three times, and the average value (mean ± SD) was calculated. The experimental data were fitted by Graphpad software to draw a cell survival curve.
[0114] 2. Experimental results
[0115] The cytotoxicity of isoliquiritigenin and isoliquiritigenin oral nanoformulation on various cells Fig.10As shown in the figure, it can be seen that isoliquiritigenin and isoliquiritigenin oral nanoformulations have low cytotoxicity to normal human breast cells and normal human liver cells, and have selective cytotoxicity to triple-negative breast cancer cells. The results show that isoliquiritigenin oral nanoformulations have potential as anti-tumor drugs.
[0116] Example 6
[0117] Evaluation of the in vivo antitumor activity of isoliquiritigenin oral nanoformulation
[0118] 1. Experimental methods
[0119] This example is used to detect the in vivo anti-tumor effect of oral nanoformulations of isoliquiritigenin. In this example, immunodeficient nude mice (BALB / c Nude Mice) were subcutaneously inoculated with MDA-MB-231 triple-negative breast cancer cells to establish an in vivo tumor model and evaluate the in vivo anti-tumor activity of oral nanoformulations of isoliquiritigenin.
[0120] BALB / c Nude Mice aged 4 to 6 weeks were selected and the number of cells was about 5 to 6 × 10 6 MDA-MB-231 cells were inoculated near the subcutaneous fat pad of mice at a cell density of 100 / 0.1 mL PBS to construct a triple-negative breast cancer tumor model. When the tumor grew to 150-200 mm 3 After about 5-6 days, the mice were randomly divided into groups (n=6) according to body weight and tumor volume to ensure that the initial values of body weight and tumor volume of each group were consistent, and oral administration was started.
[0121] Experimental groups: saline group (blank control group), blank oral nanoformulation group (comparative example 1); isoliquiritigenin-sodium carboxymethylcellulose (free isoliquiritigenin) group, isoliquiritigenin nanoformulation group (isoliquiritigenin nanoformulation). The average weight of mice is calculated as 20g, and each mouse needs to be gavaged with 0.8mg of free isoliquiritigenin, and the single gavage volume is 500μL. Weigh the free isoliquiritigenin powder and place it in a mortar, and add a pre-prepared 0.5% sodium carboxymethylcellulose aqueous solution (w / v) dropwise, grind quickly, and prepare a 1.6mg / mL free isoliquiritigenin-sodium carboxymethylcellulose suspension. Dosage and cycle: isoliquiritigenin-sodium carboxymethylcellulose group, 40mg / kg / day; isoliquiritigenin oral nanoformulation group (Example 1), 40mg / kg / day, oral gavage, once a day, for 16 consecutive days.
[0122] Observation indicators: The weight of mice and the long and short diameters of tumors were measured every 3 days, and the tumor volume (length × width 2 ×0.5), and observe for diarrhea, convulsions, rash, significant weight loss, and other reactions.
[0123] 2. Experimental results
[0124] The changes of body weight and tumor volume of nude mice in each group are as follows Fig.11 As shown. The results showed that during the administration of the oral nanoformulation of isoliquiritigenin at a dose of 40 mg / kg / day, no rash, diarrhea, death, etc. were found in the animals. The oral nanoformulation of isoliquiritigenin had a significant inhibitory effect on the in vivo growth of MDA-MB-231 triple-negative breast cancer tumors, and the tumor growth inhibition rate was 31.25% of that of the normal saline control group, and its effect of inhibiting tumor growth was about 2 times higher than that of free isoliquiritigenin. The oral nanoformulation containing isoliquiritigenin provided by the present invention can more effectively inhibit the development of triple-negative breast cancer tumors, with less side effects, and has advantages as a new oral anti-tumor drug.
Claims
1. An oral nanoformulation, comprising isoliquiritigenin and excipients, wherein the excipients include zein, casein, soybean lecithin and cholesterol, in, The mass ratio of isoliquiritigenin to auxiliary materials is 1:2-30; relative to 1 gram of isoliquiritigenin, the amount of zein is 0.2-2 grams, the amount of casein is 0.2-2 grams, the amount of soybean lecithin is 2-20 grams, and the amount of cholesterol is 1-5 grams; The preparation method of the oral nanoformulation comprises the following steps: (1) dissolving isoliquiritigenin, soybean lecithin, cholesterol and zein in an ethanol aqueous solution to prepare a solution A; (2) dissolving casein in pure water to prepare solution B; (3) Solution A is added dropwise into solution B, and the mixture is stirred until the ethanol is completely evaporated. The mixture is filtered through a filter membrane to obtain an oral nanosuspension.
2. The oral nanoformulation according to claim 1, wherein The mass ratio of isoliquiritigenin to auxiliary materials is 1:5-20.
3. The oral nanoformulation according to claim 1, wherein Relative to 1 gram of isoliquiritigenin, the amount of zein is 0.2-1 gram, the amount of casein is 0.2-1 gram, the amount of soybean lecithin is 5-15 grams, and the amount of cholesterol is 1-4 grams.
4. The oral nanoformulation according to claim 3, wherein Relative to 1 gram of isoliquiritigenin, the amount of zein is 0.2-0.5 gram, the amount of casein is 0.2-0.5 gram, the amount of soybean lecithin is 8-12 gram, and the amount of cholesterol is 1-3 gram.
5. The oral nanoformulation according to claim 1, wherein The average particle size of the oral nano preparation is 10 to 1000 nm.
6. The oral nanoformulation according to claim 5, wherein: The average particle size of the oral nano preparation is 20 to 200 nm.
7. The oral nanoformulation according to claim 1, wherein The encapsulation efficiency of the oral nanoformulation is up to 95%.
8. The oral nanoformulation according to any one of claims 1 to 7, wherein The oral nanoformulation is used to treat or inhibit triple-negative breast cancer.
9. The oral nanoformulation according to claim 1, wherein The preparation method further comprises: (4) adding a protective agent to the nanosuspension prepared in step (3) and freeze-drying the nanosuspension to prepare a freeze-dried powder.
10. The oral nanoformulation according to claim 1, wherein The ethanol aqueous solution described in step (1) is 60 to 95 weight % ethanol aqueous solution.
11. The oral nanoformulation according to claim 10, wherein: The ethanol aqueous solution described in step (1) is 80 to 95 weight % ethanol aqueous solution.
12. The oral nanoformulation according to claim 1, wherein in step (1) of the preparation method, the amount of the ethanol aqueous solution is 0.2 to 2 liters relative to 1 gram of isoliquiritigenin.
13. The oral nanoformulation according to claim 12, wherein: Relative to 1 gram of isoliquiritigenin, the dosage of the ethanol aqueous solution is 0.2 to 1 liter.
14. The oral nanoformulation according to claim 13, wherein: Relative to 1 gram of isoliquiritigenin, the dosage of the ethanol aqueous solution is 0.2 to 0.5 liter.
15. The oral nanoformulation according to claim 1, wherein in step (2) of the preparation method, the amount of pure water used is 1 to 10 liters relative to 1 gram of isoliquiritigenin.
16. The oral nanoformulation according to claim 15, wherein The amount of pure water used is 2 to 8 liters relative to 1 gram of isoliquiritigenin.
17. The oral nanoformulation according to claim 16, wherein The amount of pure water used is 2 to 6 liters relative to 1 gram of isoliquiritigenin.
18. The oral nanoformulation according to claim 1, wherein: The volume ratio of solution A obtained in step (1) of the preparation method to solution B obtained in step (2) is 1:2-5.
19. The oral nanoformulation according to claim 1, wherein: In step (3) of the preparation method, magnetic heating and stirring are adopted, the rotation speed is 400-1000 r / min, the heating temperature is 35-50° C., and the heating and stirring time is 1-6 h.
20. The oral nanoformulation according to claim 1, wherein The filter membrane described in step (3) of the preparation method is a 0.45 μm filter membrane.
21. The oral nanoformulation according to claim 9, wherein The protective agent is one or more of trehalose, mannose, mannitol and sucrose.
22. The oral nanoformulation according to claim 21, wherein The protective agent is mannose.
23. The oral nanoformulation according to claim 9, wherein The dosage of the protective agent is 2-10%, unit: g / 100mL.
24. The oral nanoformulation according to claim 23, wherein The dosage of the protective agent is 4-6%, unit: g / 100mL.
Citation Information
Patent Citations
Isoliquiritigenin nanosuspension and preparation method and application thereof
CN110859802A
Preparation and application of isoliquiritigenin albumin nano preparation
CN110898031A
Isoliquiritigenin nanoemulsion and preparation method thereof
CN111135142A
